BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 17070171)

  • 1. Role of amiodarone or implantable cardioverter/defibrillator in patients with atrial fibrillation and heart failure.
    Singh SN; Poole J; Anderson J; Hellkamp AS; Karasik P; Mark DB; Lee KL; Bardy GH;
    Am Heart J; 2006 Nov; 152(5):974.e7-11. PubMed ID: 17070171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Persistent atrial fibrillation is associated with appropriate shocks and heart failure in patients with left ventricular dysfunction treated with an implantable cardioverter defibrillator.
    Rienstra M; Smit MD; Nieuwland W; Tan ES; Wiesfeld AC; Anthonio RL; Van den Berg MP; Van Veldhuisen DJ; Van Gelder IC
    Am Heart J; 2007 Jan; 153(1):120-6. PubMed ID: 17174649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relation of advanced heart failure symptoms to risk of inappropriate defibrillator shocks.
    Hreybe H; Ezzeddine R; Barrington W; Bazaz R; Jain S; Ngwu O; Saba S
    Am J Cardiol; 2006 Feb; 97(4):544-6. PubMed ID: 16461053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomised, controlled study of rate versus rhythm control in patients with chronic atrial fibrillation and heart failure: (CAFE-II Study).
    Shelton RJ; Clark AL; Goode K; Rigby AS; Houghton T; Kaye GC; Cleland JG
    Heart; 2009 Jun; 95(11):924-30. PubMed ID: 19282313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atrial fibrillation predicts appropriate shocks in primary prevention implantable cardioverter-defibrillator patients.
    Smit MD; Van Dessel PF; Rienstra M; Nieuwland W; Wiesfeld AC; Tan ES; Anthonio RL; Van Veldhuisen DJ; Van Gelder IC
    Europace; 2006 Aug; 8(8):566-72. PubMed ID: 16864611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term comparison of the implantable cardioverter defibrillator versus amiodarone: eleven-year follow-up of a subset of patients in the Canadian Implantable Defibrillator Study (CIDS).
    Bokhari F; Newman D; Greene M; Korley V; Mangat I; Dorian P
    Circulation; 2004 Jul; 110(2):112-6. PubMed ID: 15238454
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of sinus rhythm return during defibrillation testing in patients with permanent atrial fibrillation undergoing implantation of a cardioverter-defibrillator.
    Lelakowski J; Tomala I; Cmiel A; Rydlewska A; Majewski J; Małecka B
    Kardiol Pol; 2011; 69(1):17-22. PubMed ID: 21267958
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amiodarone prophylaxis for atrial fibrillation of high-risk patients after coronary bypass grafting: a prospective, double-blinded, placebo-controlled, randomized study.
    Budeus M; Hennersdorf M; Perings S; Röhlen S; Schnitzler S; Felix O; Reimert K; Feindt P; Gams E; Lehmann N; Wieneke H; Sack S; Erbel R; Perings C
    Eur Heart J; 2006 Jul; 27(13):1584-91. PubMed ID: 16760210
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic importance of atrial fibrillation in implantable cardioverter-defibrillator patients.
    Borleffs CJ; van Rees JB; van Welsenes GH; van der Velde ET; van Erven L; Bax JJ; Schalij MJ
    J Am Coll Cardiol; 2010 Mar; 55(9):879-85. PubMed ID: 20185038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of atrial arrhythmias in a primary prevention ICD population.
    van Gelder IC; Phan HM; Wilkoff BL; Brown ML; Rogers T; Peterson BJ; Birgersdotter-Green UM
    Pacing Clin Electrophysiol; 2011 Sep; 34(9):1070-9. PubMed ID: 21605131
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quality of life and exercise performance in patients in sinus rhythm versus persistent atrial fibrillation: a Veterans Affairs Cooperative Studies Program Substudy.
    Singh SN; Tang XC; Singh BN; Dorian P; Reda DJ; Harris CL; Fletcher RD; Sharma SC; Atwood JE; Jacobson AK; Lewis HD; Lopez B; Raisch DW; Ezekowitz MD;
    J Am Coll Cardiol; 2006 Aug; 48(4):721-30. PubMed ID: 16904540
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
    Bardy GH; Lee KL; Mark DB; Poole JE; Packer DL; Boineau R; Domanski M; Troutman C; Anderson J; Johnson G; McNulty SE; Clapp-Channing N; Davidson-Ray LD; Fraulo ES; Fishbein DP; Luceri RM; Ip JH;
    N Engl J Med; 2005 Jan; 352(3):225-37. PubMed ID: 15659722
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison between oral antiarrhythmic drugs in the prevention of atrial fibrillation after cardiac surgery: the pilot study of prevention of postoperative atrial fibrillation (SPPAF), a randomized, placebo-controlled trial.
    Auer J; Weber T; Berent R; Puschmann R; Hartl P; Ng CK; Schwarz C; Lehner E; Strasser U; Lassnig E; Lamm G; Eber B;
    Am Heart J; 2004 Apr; 147(4):636-43. PubMed ID: 15077078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of thromboembolism in heart failure: an analysis from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT).
    Freudenberger RS; Hellkamp AS; Halperin JL; Poole J; Anderson J; Johnson G; Mark DB; Lee KL; Bardy GH;
    Circulation; 2007 May; 115(20):2637-41. PubMed ID: 17485579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison between atrial fibrillation-triggered implantable cardioverter-defibrillator (ICD) shocks and inappropriate shocks caused by lead failure: different impact on prognosis in clinical practice.
    Kleemann T; Hochadel M; Strauss M; Skarlos A; Seidl K; Zahn R
    J Cardiovasc Electrophysiol; 2012 Jul; 23(7):735-40. PubMed ID: 22313314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ventricular proarrhythmic effects of atrial fibrillation are modulated by depolarization and repolarization anomalies in patients with left ventricular dysfunction.
    Lemola K; Khan R; Nattel S; Talajic M; Roy D; Guerra PG; Lemola S; Dubuc M; Thibault B; Macle L; Khairy P
    Pacing Clin Electrophysiol; 2009 Jan; 32(1):99-105. PubMed ID: 19140919
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Appropriate evaluation and treatment of heart failure patients after implantable cardioverter-defibrillator discharge: time to go beyond the initial shock.
    Mishkin JD; Saxonhouse SJ; Woo GW; Burkart TA; Miles WM; Conti JB; Schofield RS; Sears SF; Aranda JM
    J Am Coll Cardiol; 2009 Nov; 54(22):1993-2000. PubMed ID: 19926003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primary prevention with defibrillator therapy in women: results from the Sudden Cardiac Death in Heart Failure Trial.
    Russo AM; Poole JE; Mark DB; Anderson J; Hellkamp AS; Lee KL; Johnson GW; Domanski M; Bardy GH
    J Cardiovasc Electrophysiol; 2008 Jul; 19(7):720-4. PubMed ID: 18373605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inappropriate implantable cardioverter-defibrillator shocks in MADIT II: frequency, mechanisms, predictors, and survival impact.
    Daubert JP; Zareba W; Cannom DS; McNitt S; Rosero SZ; Wang P; Schuger C; Steinberg JS; Higgins SL; Wilber DJ; Klein H; Andrews ML; Hall WJ; Moss AJ;
    J Am Coll Cardiol; 2008 Apr; 51(14):1357-65. PubMed ID: 18387436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Device complications and inappropriate implantable cardioverter defibrillator shocks in patients with hypertrophic cardiomyopathy.
    Lin G; Nishimura RA; Gersh BJ; Phil D; Ommen SR; Ackerman MJ; Brady PA
    Heart; 2009 May; 95(9):709-14. PubMed ID: 19282314
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.